ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2–Positive Gastric or Gastroesophageal Junction Adenocarcinoma

PURPOSE: Zolbetuximab, an IgG1 monoclonal antibody, binds to claudin 18.2 (CLDN18.2) and mediates tumor cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. We sought to examine zolbetuximab combinations in CLDN18.2-positive HER2-negative gastric/gastroe...

Descripción completa

Detalles Bibliográficos
Autores principales: Klempner, Samuel J., Lee, Keun-Wook, Shitara, Kohei, Metges, Jean-Phillippe, Lonardi, Sara, Ilson, David H., Fazio, Nicola, Kim, Tae Yong, Bai, Li-Yuan, Moran, Diarmuid, Yang, Jianning, Arozullah, Ahsan, Park, Jung Wook, Raizer, Jeffrey J., Bang, Yung-Jue, Shah, Manish A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Clinical Trials: Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543966/
https://www.ncbi.nlm.nih.gov/pubmed/37490286
http://dx.doi.org/10.1158/1078-0432.CCR-23-0204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543966/
https://www.ncbi.nlm.nih.gov/pubmed/37490286
http://dx.doi.org/10.1158/1078-0432.CCR-23-0204

Ejemplares similares